VSSPY yields 13.95% · JNJ yields 2.14%● Live data
📍 VSSPY pulled ahead of the other in Year 1
Combined, VSSPY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VSSPY + JNJ for your $10,000?
Valid Soluções S.A. provides security printing services for payment and mobile solutions, identity solutions, digital marketing, and digital certification worldwide. It operates through Means of Payment, Identification, and Mobile segments. The Means of Payment segment offers integrated products and solutions, such as chip and magnetic stripe cards, gift cards, check printing, invoices, and bank statements, as well as solutions in radio frequency identification, contactless cards, and mobile payments. The Identification segment provides physical and electronic solutions, such as data collection, storage and management, security prints, recognition, and digital printing. Its solutions are used in the generation of computerized systems for the administration of databases, collection of biometric data, printing and customization of official identification documents, solutions for smart cities, and traceable stamps. The Mobile segment offers services of issuing statements and technologies for use in cell phones, and digital mobility, such as NFC, TSM, and HCE solutions for mobile service providers. It also develops technologies for use in cell phones, such as recharge and payment and production of cards intended for telecommunications. The company serves state governments and government agencies, large financial institutions, telecommunications companies, retailers, agriculture cooperatives, and self-employed professionals. The company was formerly known as Valid Soluções e Serviços de Segurança em Meios de Pagamento e Identificação S.A. and changed its name to Valid Soluções S.A. in August 2018. Valid Soluções S.A. was founded in 1957 and is headquartered in Rio de Janeiro, Brazil.
Full VSSPY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.